Discounted Cash Flow (DCF) Analysis Levered
Amicus Therapeutics, Inc. (FOLD)
$13.17
-0.05 (-0.38%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 36.93 | 91.24 | 182.24 | 260.89 | 305.51 | 540.04 | 954.61 | 1,687.42 | 2,982.78 | 5,272.53 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -215.49 | -299.96 | -250.42 | -233.29 | -202.49 | -1,301.88 | -2,301.27 | -4,067.85 | -7,190.56 | -12,710.43 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -4.53 | -6.31 | -20.01 | -3.23 | -3.88 | -35.27 | -62.35 | -110.22 | -194.83 | -344.38 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -220.01 | -306.26 | -270.43 | -236.52 | -206.38 | -1,337.15 | -2,363.62 | -4,178.07 | -7,385.39 | -13,054.82 |
Weighted Average Cost Of Capital
| Share price | $ 13.17 |
|---|---|
| Beta | 0.852 |
| Diluted Shares Outstanding | 271.42 |
| Cost of Debt | |
| Tax Rate | -3.69 |
| After-tax Cost of Debt | 7.38% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 7.546 |
| Total Debt | 440.13 |
| Total Equity | 3,574.63 |
| Total Capital | 4,014.76 |
| Debt Weighting | 10.96 |
| Equity Weighting | 89.04 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 36.93 | 91.24 | 182.24 | 260.89 | 305.51 | 540.04 | 954.61 | 1,687.42 | 2,982.78 | 5,272.53 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -215.49 | -299.96 | -250.42 | -233.29 | -202.49 | -1,301.88 | -2,301.27 | -4,067.85 | -7,190.56 | -12,710.43 |
| Capital Expenditure | -4.53 | -6.31 | -20.01 | -3.23 | -3.88 | -35.27 | -62.35 | -110.22 | -194.83 | -344.38 |
| Free Cash Flow | -220.01 | -306.26 | -270.43 | -236.52 | -206.38 | -1,337.15 | -2,363.62 | -4,178.07 | -7,385.39 | -13,054.82 |
| WACC | ||||||||||
| PV LFCF | -864.97 | -1,421.90 | -2,337.43 | -3,842.43 | -6,316.47 | |||||
| SUM PV LFCF | -21,252.84 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 7.53 |
| Free cash flow (t + 1) | -13,315.92 |
| Terminal Value | -240,794.13 |
| Present Value of Terminal Value | -167,493.39 |
Intrinsic Value
| Enterprise Value | -188,746.23 |
|---|---|
| Net Debt | 194.93 |
| Equity Value | -188,941.16 |
| Shares Outstanding | 271.42 |
| Equity Value Per Share | -696.12 |